首页> 美国卫生研究院文献>British Medical Journal >Growth hormone insulin and prolactin secretion in anorexia nervosa and obesity during bromocriptine treatment.
【2h】

Growth hormone insulin and prolactin secretion in anorexia nervosa and obesity during bromocriptine treatment.

机译:溴隐亭治疗期间神经性厌食症和肥胖症中的生长激素胰岛素和催乳激素分泌。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We studied secretion of growth hormone (GH), insulin, and prolactin in eight women with anorexia nervosa and nine women with refractory obesity before and during treatment with bromocriptine, 10 mg/day. In the anorexic patients the raised plasma GH concentrations occurring during an oral glucose tolerance test fell significantly while on bromocriptine treatment, but there was no change in plasma insulin or blood glucose concentrations. In the obese patients, however, plasma GH concentrations remained low during the oral glucose tolerance test, and were not modified by bromocriptine. Blood glucose and plasma insulin concentrations were also unchanged. Plasma GH and plasma 11-hydroxycorticosteroid responses to insulin-induced hypoglycaemia were unaffected. Serum prolactin concentrations which were raised in five anorexic patients and marginally raised in two obese subjects, fell significantly in both groups during treatment. We observed no consistent weight changes in either groups.
机译:我们研究了溴隐亭治疗前和治疗期间10毫克/天的8例神经性厌食症和9例难治性肥胖妇女的生长激素(GH),胰岛素和催乳激素的分泌。在厌食症患者中,口服溴隐亭治疗期间,口服葡萄糖耐量试验期间出现的血浆GH浓度升高明显下降,但血浆胰岛素或血糖浓度没有变化。但是,在肥胖患者中,口服葡萄糖耐量试验期间血浆GH浓度仍然很低,而溴隐亭并未对其进行调节。血糖和血浆胰岛素浓度也未改变。血浆GH和血浆11-羟基皮质类固醇对胰岛素诱导的低血糖反应不受影响。在治疗期间,两组中五名厌食症患者的血清催乳素浓度均升高,而两名肥胖患者的血清催乳素浓度则略有下降。我们在两组中均未观察到一致的体重变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号